达拉图穆马布基组合疗法作为复发性阻断性多发性骨髓瘤的二线治疗:单中心体验
Oscar C Y Yang1,2, Yi-Hao Chiang1,2,3, Caleb Gonshen Chen1,2,3
1Department of Internal Medicine, Division of Hematology and Oncology, MacKay Memorial Hospital, Taipei, Taiwan.
Cancer reports (Hoboken, N.J.)
|November 29, 2025
概括
达拉图穆马布在现实世界二线治疗中对复发性/耐药性多发性骨髓瘤 (RRMM) 显示出有希望的疗效和适度的耐受性. 这项研究为接受达拉图穆马布治疗的RRMM患者提供了宝贵的临床见解.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 达拉图马布是第一个针对CD38的单克隆抗体,用于复发性/耐火性多发性髓瘤 (RRMM).
- 随机对照试验支持其在预先治疗多发性骨髓瘤的二线治疗中的有效性.
- 关于达拉图穆马布在临床实践中的实际使用数据有限.
研究的目的:
- 为了评估daratumumab在RRMM患者中的实际临床结果和不良影响.
- 评估达拉图穆马布在日常临床实践中作为二线治疗的疗效.
主要方法:
- 观测案例系列与回顾性图表审查.
- 包括接受达拉图马布组合治疗的多发性骨髓瘤患者.
- 主要终点:无进展的生存率;次要终点:整体反应率,不良反应和随后的治疗.
主要成果:
- 总体应答率为76.5% (13/17名患者).
- 在二线设置中,无进展生存时间的中位数为20个月.
- 常见的不良反应:中性质减退 (52.9%),血小板减退 (64.7%),贫血 (35.7%) 和肺炎 (35.3%).
结论:
- 达拉图马布在组合治疗中在台湾RRMM患者中显示出有前途的疗效.
- 药物在二线治疗环境中表现出适度的耐受性.
- 这一单一中心的经验为达拉图穆马布使用提供了有价值的现实世界的证据.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K